DFX Intelligence
The names on this page are hidden. Create a free account to reveal 5 records a month, or get Private Credit Intelligence at $249 a month for every name. Every figure, date and source on this page is public either way.
Borrower
C••••••••• I••
Biotechnologygroup grade Aoff every schedule since Sep 30, 2025sponsor unattributed
Nothing material in the last 200 days. Last change: 30 Sep 2025, Consensus mark 105¢ on cost, up from 103¢ a year ago, 103¢ last quarter.
Mark path, consensus per quarter end
103¢ · 103¢ · 103¢ · 103¢ · 105¢Q3 2024 to Q3 2025
Where each lender marks it on the first lien term loan, 4 points apart
102¢106¢
Principal held
at least $52.9M
sum of BDC pieces, a lower bound
Fair value
$56.4M
105c on cost, debt pieces
Unfunded
Not disclosed
commitments not yet drawn
BDC lenders
4
4 on the latest quarter
Facilities
2
0 equity pieces beside them
Next maturity
Jan 31, 2028
no dated debt inside 24 months
On the tape since
Dec 31, 2022
latest Sep 30, 2025
Events
3
dated, non-routine
Lender marks
each lender's own fair value over cost at Sep 30, 2025, folded to one row per lender
| Lender | Exposure | Current mark | QoQ change |
|---|---|---|---|
| S•• I••••••••• C•••• | $36.2M | 106¢ | +2 pts |
| S•• P•••••• C••••• I••••• B•• L•• | $12.1M | 104¢ | +2 pts |
| S•• H• B•• L•• | $3.35M | 102¢ | +2 pts |
| S•• P•••••• C••••• B•• I• L•• | $1.28M | 102¢ | +2 pts |
Every BDC piece · 4 positions across 4 lenderslargest principal first, with instrument and rate
| BDC | Instrument | Principal | Fair value | Rate |
|---|---|---|---|---|
| S•• I••••••••• C•••• | term loan first lien | F•••• L••• L••• S•••••• S••••• S•••••• L•••• | 12/2022 | 1/2028 | $36.2M | $38.8M 106c | SOFR+620 bp |
| S•• P•••••• C••••• I••••• B•• L•• | term loan first lien I••••••• B••••••••• S••••• above I•••• S+620 F•••• 2.75% I••••••• R••• 10.45% A••••••••• D | $12.1M | $12.8M 104c | SOFR+620 bp |
| S•• H• B•• L•• | term loan first lien B••• D•••/S••••• S•••••• L•••• | 12/2022 | 1/2028 | $3.3M | $3.5M 102c | SOFR+620 bp |
| S•• P•••••• C••••• B•• I• L•• | term loan first lien B••• D•••/S••••• S•••••• L•••• — 268.6% | 10/2023 | 1/2028 | $1.3M | $1.3M 102c | S+620 bp |
Capital structure as the BDCs see it
latest quarter end Sep 30, 2025
| Facility | Held | On cost | Pricing | Maturity | BDCs |
|---|---|---|---|---|---|
| first lien term loan first lien exited Sep 30, 2025 | at least $52.9M | 105c | SOFR+620 bp | Jan 31, 2028 | 4 |
| other lien unstated exited Dec 31, 2022 | at least $9.7M | 100c | S+620 bp | Jan 1, 2028 | 1 |
Through time
the borrower's pieces summed across BDCs, every quarter end
| Quarter end | BDCs | Principal held | Fair value | On cost | PIK pieces |
|---|---|---|---|---|---|
| Sep 30, 2025 | 4 | $52.9M | $56.4M | 105c | 0 |
| Jun 30, 2025 | 4 | $52.9M | $55.1M | 103c | 0 |
| Mar 31, 2025 | 4 | $52.9M | $55.1M | 103c | 0 |
| Dec 31, 2024 | 4 | $154M | $160M | 103c | 0 |
All 10 quartersShow fewer
| Quarter end | BDCs | Principal held | Fair value | On cost | PIK pieces |
|---|---|---|---|---|---|
| Sep 30, 2024 | 4 | $52.9M | $54.8M | 103c | 0 |
| Jun 30, 2024 | 4 | $52.5M | $54.3M | 103c | 0 |
| Mar 31, 2024 | 4 | $52.5M | $54.2M | 103c | 0 |
| Dec 31, 2023 | 4 | $129M | $129M | 100c | 0 |
| Sep 30, 2023 | 3 | $39.1M | $39.2M | 100c | 0 |
| Dec 31, 2022 | 3 | $78.3M | $78.1M | 100c | 0 |
What changed
- Facility left every BDC scheduleSep 30, 2025
- New borrower on a BDC scheduleDec 31, 2022
- Facility left every BDC scheduleDec 31, 2022
Sponsor
No sponsor attribution: no portfolio page, deal announcement or Form D signer consensus names an owner for this borrower group.
Identity
- Group key
- CERAPEDICSderivedthe codename stem after legal suffixes and deal words
- Spellings
- 1 across 4 BDCsderived
- Industry
- Biotechnologyreportedas one filer wrote it